| scholarly article | Q13442814 |
| P50 | author | Josef Penninger | Q1674391 |
| P2093 | author name string | J Li | |
| Y Y Kong | |||
| R Elliott | |||
| S Scully | |||
| W J Boyle | |||
| T Sasaki | |||
| E B Voura | |||
| J E Fata | |||
| R A Moorehead | |||
| R Khokha | |||
| D L Lacey | |||
| J Irie-Sasaki | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse | Q24315716 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| Colony stimulating factor 1 is required for mammary gland development during pregnancy | Q24563619 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Enforced Expression of Bcl-2 in Monocytes Rescues Macrophages and Partially Reverses Osteopetrosis in op/op Mice | Q28593712 | ||
| Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities | Q29615568 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Regulation of mammary gland development by tissue interaction | Q33603542 | ||
| Parathyroid hormone-related protein: a developmental regulatory molecule necessary for mammary gland development | Q33603548 | ||
| Prolactin and mammary gland development | Q33603566 | ||
| Cell biology of the osteoclast | Q33700885 | ||
| The genetic transformation of bone biology | Q33796568 | ||
| Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype | Q33939814 | ||
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 | ||
| RANKing the importance of measles virus in Paget's disease | Q40326890 | ||
| Exploring the role of sex steroids through studies of receptor deficient mice | Q47861980 | ||
| Stat5a is mandatory for adult mammary gland development and lactogenesis. | Q48055024 | ||
| Timp-1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development. | Q52175987 | ||
| Breast cancer cells interact with osteoblasts to support osteoclast formation | Q73025244 | ||
| Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord | Q73766127 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Tumor necrosis factor receptor superfamily, member 11a, NFKB activator | Q14900987 |
| Tumor necrosis factor (ligand) superfamily, member 11 | Q14905570 | ||
| P304 | page(s) | 41-50 | |
| P577 | publication date | 2000-09-29 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | |
| P478 | volume | 103 |
| Q37589815 | A DNA segment spanning the mouse Tnfsf11 transcription unit and its upstream regulatory domain rescues the pleiotropic biologic phenotype of the RANKL null mouse |
| Q57184035 | A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF |
| Q42007592 | A T Cell View of the Bone Marrow |
| Q24599024 | A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway |
| Q35029498 | A local basis for progesterone action during mammary tumorigenesis - no longer RANK and file |
| Q43560074 | A novel osteoblast-derived C-type lectin that inhibits osteoclast formation |
| Q48541886 | AIRE's CARD revealed, a new structure for central tolerance provokes transcriptional plasticity |
| Q37706111 | Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer |
| Q36041423 | Accelerated apoptosis in the Timp-3-deficient mammary gland |
| Q44336479 | Activating transcription factor 4 overexpression inhibits proliferation and differentiation of mammary epithelium resulting in impaired lactation and accelerated involution |
| Q33748998 | Administration of RANKL boosts thymic regeneration upon bone marrow transplantation |
| Q36655984 | Alveolar and lactogenic differentiation |
| Q90695277 | Amphiregulin mediates the hormonal regulation on Rspondin-1 expression in the mammary gland |
| Q47554048 | An Rb family-independent E2F3 transcription factor variant impairs STAT5 signaling and mammary gland remodeling during pregnancy in mice |
| Q53392614 | An essential link to mammary cancer? |
| Q38075495 | Animal model for mammary tumor growth in the bone microenvironment |
| Q26863493 | Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences |
| Q37923343 | Anti-cancer actions of denosumab |
| Q34774678 | Antibody-mediated "universal" osteoclast targeting platform using calcitonin as a model drug. |
| Q36928773 | Association analyses suggest the effects of RANK and RANKL on age at menarche in Chinese women. |
| Q37632537 | Basal cell signaling by p63 controls luminal progenitor function and lactation via NRG1. |
| Q28265584 | Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab |
| Q46528153 | Beta-galactosidase detection as an indicator of endogenous PTHrP in cartilage |
| Q43559838 | Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase |
| Q50642672 | Biochemical markers of bone resorption are present in human milk: implications for maternal and neonatal bone metabolism. |
| Q21195419 | Biology of RANK, RANKL, and osteoprotegerin |
| Q34366449 | Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond |
| Q35145622 | Biology of the TRANCE axis |
| Q35111940 | Biotechnological approach for systemic delivery of membrane Receptor Activator of NF-κB Ligand (RANKL) active domain into the circulation. |
| Q37155255 | Bone Turnover Markers and Osteoprotegerin in Uncomplicated Pregnancy |
| Q59035695 | Bone-disease drug could treat breast cancer |
| Q28087676 | Bone-targeted therapy in metastatic breast cancer - all well-established knowledge? |
| Q54748826 | Bovine mammary gene expression profiling using a cDNA microarray enhanced for mammary-specific transcripts. |
| Q42586718 | CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany |
| Q28304012 | CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis |
| Q57184580 | Can osteoclasts be excluded? (Reply) |
| Q38991293 | Can we prevent BRCA1-associated breast cancer by RANKL inhibition? |
| Q39014552 | Cell lineage determinants as regulators of breast cancer metastasis |
| Q43713956 | Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17beta-estradiol during the estrous cycle |
| Q24321735 | Central control of fever and female body temperature by RANKL/RANK |
| Q64057496 | Changes in bone metabolic profile associated with pregnancy or lactation |
| Q28216134 | Changes in the cytologic distribution of heparin/heparan sulfate interacting protein/ribosomal protein L29 (HIP/RPL29) during in vivo and in vitro mouse mammary epithelial cell expression and differentiation |
| Q30540259 | Chinese Herbal Formula Huo-Luo-Xiao-Ling Dan Protects against Bone Damage in Adjuvant Arthritis by Modulating the Mediators of Bone Remodeling |
| Q58805499 | Circulating Levels of Bone and Inflammatory Markers in Gestational Diabetes Mellitus |
| Q38682103 | Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort |
| Q57796276 | Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL) and Mammographic Density in Premenopausal Women |
| Q35184335 | Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders |
| Q40348336 | Collagen type I signaling reduces the expression and the function of human receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes |
| Q36158922 | Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets |
| Q42439949 | Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. |
| Q24619669 | Control of RANKL gene expression |
| Q37069494 | Control of adult stem cells in vivo by a dynamic physiological environment: diet-dependent systemic factors in Drosophila and beyond |
| Q43103606 | Control of mammary stem cell function by steroid hormone signalling. |
| Q33775316 | Correlation of mammographic density and serum calcium levels in patients with primary breast cancer |
| Q36240642 | Cripto-1 ablation disrupts alveolar development in the mouse mammary gland through a progesterone receptor-mediated pathway. |
| Q27635130 | Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity |
| Q28256059 | Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism |
| Q28586470 | Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform |
| Q38832148 | Deletion of a Distal RANKL Gene Enhancer Delays Progression of Atherosclerotic Plaque Calcification in Hypercholesterolemic Mice. |
| Q36808470 | Deletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice |
| Q93016733 | Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study |
| Q85059954 | Denosumab for the Treatment of Osteoporosis |
| Q37986124 | Denosumab for treatment of breast cancer bone metastases and beyond |
| Q37974570 | Denosumab in patients with cancer-a surgical strike against the osteoclast |
| Q36056922 | Denosumab in postmenopausal osteoporosis: what the clinician needs to know |
| Q38712724 | Denosumab: an Emerging Therapy in Pediatric Bone Disorders |
| Q40706650 | Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland |
| Q28295303 | Disorders of Bone Remodeling |
| Q33854404 | Distinct roles of the three Akt isoforms in lactogenic differentiation and involution |
| Q36924384 | ER and PR signaling nodes during mammary gland development |
| Q84449609 | Effects of RANKL on the thymic medulla |
| Q37441693 | Effects of RANKL-Targeted Therapy in Immunity and Cancer |
| Q36593639 | Effects of electromagnetic radiation exposure on bone mineral density, thyroid, and oxidative stress index in electrical workers |
| Q33840456 | Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation |
| Q57184743 | Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells |
| Q33610623 | Epidermal growth factor receptor (EGFR) signaling is a key mediator of hormone-induced leukocyte infiltration in the pubertal female mammary gland |
| Q28594617 | Essential role for ADAM19 in cardiovascular morphogenesis |
| Q36372569 | Estrogen and progesterone are critical regulators of Stat5a expression in the mouse mammary gland |
| Q35133898 | Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran |
| Q57881796 | Evidence for a link between TNFRSF11A and risk of breast cancer |
| Q24806283 | Experimental manipulation of radiographic density in mouse mammary gland |
| Q33583910 | Exploring codon optimization and response surface methodology to express biologically active transmembrane RANKL in E. coli |
| Q40654612 | Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactation |
| Q35769514 | Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours |
| Q39967650 | Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression |
| Q44991866 | Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. |
| Q34539976 | Fas-independent T-cell apoptosis by dendritic cells controls autoimmune arthritis in MRL/lpr mice |
| Q36643034 | Fatal attraction: why breast cancer cells home to bone. |
| Q59799443 | Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma |
| Q42972436 | From bone to breast and back - the bone cytokine RANKL and breast cancer |
| Q35348210 | From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer |
| Q35659426 | From the ranks of mammary progesterone mediators, RANKL takes the spotlight |
| Q44770240 | Functional development of the mammary gland: use of expression profiling and trajectory clustering to reveal changes in gene expression during pregnancy, lactation, and involution |
| Q36700779 | Functions of RANKL/RANK/OPG in bone modeling and remodeling |
| Q36909544 | Genes Frequently Coexpressed with Hoxc8 Provide Insight into the Discovery of Target Genes |
| Q30534404 | Genetic polymorphism of the OPG gene associated with breast cancer |
| Q81579227 | Genomewide analysis of secretory activation in mouse models |
| Q35029509 | High hopes for RANKL: will the mouse model live up to its promise? |
| Q28077637 | Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women |
| Q33845036 | Hormonal and local control of mammary branching morphogenesis |
| Q34771428 | Hormonal control of alveolar development and its implications for breast carcinogenesis |
| Q26781387 | Hormone signaling requirements for the conversion of non-mammary mouse cells to mammary cell fate(s) in vivo |
| Q36903215 | Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium |
| Q54478398 | Human receptor activator of NF-κB ligand (RANKL) induces osteoclastogenesis of primates in vitro. |
| Q44247178 | IGF-2 is a mediator of prolactin-induced morphogenesis in the breast |
| Q28508430 | IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development |
| Q84033281 | Identification and characterization of anti-osteoclastogenic peptides derived from the cytoplasmic tail of receptor activator of nuclear factor kappa B |
| Q53584487 | Identification of novel RANK polymorphisms and their putative association with low BMD among postmenopausal women. |
| Q36924500 | Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration |
| Q40230484 | Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. |
| Q36023768 | IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells |
| Q47666371 | Immunohistochemical and quantitative RT-PCR methods to assess RANK expression in normal and neoplastic canine mammary gland. |
| Q38562815 | Impact of progesterone on stem/progenitor cells in the human breast |
| Q47681521 | Increased breast tissue receptor activator of nuclear factor-κB ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women |
| Q29618116 | Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts |
| Q36289108 | Information networks in the mammary gland. |
| Q34102993 | Integrin αvβ3 drives slug activation and stemness in the pregnant and neoplastic mammary gland |
| Q37122596 | Intercellular Communication between Keratinocytes and Fibroblasts Induces Local Osteoclast Differentiation: a Mechanism Underlying Cholesteatoma-Induced Bone Destruction |
| Q44022501 | KLF5 promotes cervical cancer proliferation, migration and invasion in a manner partly dependent on TNFRSF11a expression |
| Q47250561 | Key Factors in Breast Cancer Dissemination and Establishment at the Bone: Past, Present and Future Perspectives. |
| Q34613461 | Key signaling nodes in mammary gland development and cancer: β-catenin |
| Q35749416 | Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis! |
| Q24541517 | Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis |
| Q54200830 | LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. |
| Q34396516 | Loss of SFRP1 promotes ductal branching in the murine mammary gland |
| Q45988712 | Loss of glutaredoxin 3 impedes mammary lobuloalveolar development during pregnancy and lactation. |
| Q26740086 | Mammary Development and Breast Cancer: A Wnt Perspective |
| Q34706838 | Mammary Gland Reprogramming: Metalloproteinases Couple Form with Function |
| Q24629797 | Mammary gland development |
| Q27003345 | Mammary stem cells and the differentiation hierarchy: current status and perspectives |
| Q24645591 | Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation |
| Q58582775 | Maternal RANKL Reduces the Osteopetrotic Phenotype of Null Mutant Mouse Pups |
| Q47111770 | Mechanism of M-cell differentiation accelerated by proliferation of indigenous bacteria in rat Peyer's patches |
| Q52578848 | Mechanisms involved in normal and pathological osteoclastogenesis. |
| Q41922030 | Mediators of inflammation-induced bone damage in arthritis and their control by herbal products |
| Q89881398 | Membrane expression of the estrogen receptor ERα is required for intercellular communications in the mammary epithelium |
| Q33631557 | Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios? |
| Q35664993 | Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis |
| Q35801397 | Monitoring dynamic interactions between breast cancer cells and human bone tissue in a co-culture model |
| Q49589290 | Morphological characteristics of osteopetrosis |
| Q35063276 | Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region |
| Q38155200 | Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis |
| Q60946525 | Mutations and Breast Cancer Prevention |
| Q33642546 | Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation |
| Q40538587 | Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. |
| Q28590656 | NF-Y is essential for the recruitment of RNA polymerase II and inducible transcription of several CCAAT box-containing genes |
| Q29614603 | NF-kappaB in cancer: from innocent bystander to major culprit |
| Q35592117 | NF-kappaB in mammary gland development and breast cancer |
| Q37431321 | NF-kappaΒ-inducing kinase regulates stem cell phenotype in breast cancer. |
| Q52018491 | NFATc1 expression in the developing heart valves is responsive to the RANKL pathway and is required for endocardial expression of cathepsin K. |
| Q36288731 | NHERF1/EBP50 controls lactation by establishing basal membrane polarity complexes with prolactin receptor |
| Q36382641 | Notch-induced mammary tumorigenesis does not involve the lobule-limited epithelial progenitor |
| Q34134745 | Novel vertebrate genes and putative regulatory elements identified at kidney disease and NR2E1/fierce loci |
| Q36115911 | Nucling, a novel apoptosis-associated protein, controls mammary gland involution by regulating NF-κB and STAT3. |
| Q57183997 | Nutrition and the biology of human ageing: Bone health & osteoporosis / sarcopenia / immune deficiency |
| Q35878795 | OPG Treatment Prevents Bone Loss During Lactation But Does Not Affect Milk Production or Maternal Calcium Metabolism |
| Q41135180 | OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer |
| Q38952629 | Of skin and bone: did Langerhans cells and osteoclasts evolve from a common ancestor? |
| Q28504606 | Opg, Rank, and Rankl in tooth development: co-ordination of odontogenesis and osteogenesis |
| Q30434164 | Organogenesis of the exocrine gland |
| Q36848841 | Organotropism of breast cancer metastasis |
| Q39190775 | Osteoblast-osteoclast interactions |
| Q24605866 | Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer |
| Q28593804 | Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha |
| Q34826003 | Osteoclasts are essential for TNF-alpha-mediated joint destruction |
| Q35755039 | Osteoclasts: New Insights |
| Q28267634 | Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone |
| Q35572441 | Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection |
| Q47944184 | Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems. |
| Q37544448 | Osteoimmunology: crosstalk between the immune and bone systems |
| Q92668034 | Osteoimmunology: evolving concepts in bone-immune interactions in health and disease |
| Q28294477 | Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems |
| Q34560598 | Osteoprotegerin |
| Q36273402 | Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort |
| Q81739887 | Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis |
| Q40553401 | Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development |
| Q39946634 | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone |
| Q40765947 | Osteoprotegerin ligand induces beta-casein gene expression through the transcription factor CCAAT/enhancer-binding protein beta |
| Q35088014 | Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors |
| Q35087950 | Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone |
| Q64071144 | Overview of RAW264.7 for osteoclastogensis study: Phenotype and stimuli |
| Q24295182 | PIKE-A is required for prolactin-mediated STAT5a activation in mammary gland development |
| Q35838272 | Paracrine Met signaling triggers epithelial-mesenchymal transition in mammary luminal progenitors, affecting their fate |
| Q28508026 | Paracrine-rescued lobulogenesis in chimeric outgrowths comprising progesterone-receptor-null mammary epithelium and redirected wild-type testicular cells |
| Q92854752 | Parathyroid Hormone-Related Protein (PTHrP) Accelerates Soluble RANKL Signals for Downregulation of Osteogenesis of Bone Mesenchymal Stem Cells |
| Q35071181 | Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer |
| Q40699804 | Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein |
| Q34850028 | Pediatric liver tumors and hepatic ontogenesis: common and distinctive pathways |
| Q35039448 | Peroxisome proliferator-activated receptor alpha activation during pregnancy severely impairs mammary lobuloalveolar development in mice |
| Q37810596 | Physiology and pathophysiology of the RANKL/RANK system |
| Q64104436 | Plasma RANKL levels are not associated with breast cancer risk in and mutation carriers |
| Q37699313 | Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q47834751 | Porphyrin Derivatives Inhibit the Interaction between Receptor Activator of NF-κB and Its Ligand. |
| Q61940998 | Potential role of the intestinal microbiota of the mother in neonatal immune education |
| Q37996455 | Premetastatic niche: ready for new therapeutic interventions? |
| Q37457322 | Prevention of breast cancer by RANKL/RANK blockade |
| Q34321877 | Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. |
| Q90073087 | Progesterone and Breast Cancer |
| Q42471079 | Progesterone induces adult mammary stem cell expansion |
| Q35605000 | Progesterone involvement in breast development and tumorigenesis--as revealed by progesterone receptor "knockout" and "knockin" mouse models |
| Q33998721 | Progesterone receptor action: defining a role in breast cancer |
| Q37249108 | Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells |
| Q38109029 | Progesterone signalling in breast cancer: a neglected hormone coming into the limelight |
| Q51042996 | Progesterone/RANKL is a major regulatory axis in the human breast. |
| Q21092903 | Progestin effects on cell proliferation pathways in the postmenopausal mammary gland |
| Q36578851 | Progestin-regulated luminal cell and myoepithelial cell-specific responses in mammary organoid culture |
| Q38572022 | Progestogens and risk of breast cancer: a link between bone and breast? |
| Q37064933 | Prolactin regulation of mammary gland development. |
| Q36134061 | Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis |
| Q34360755 | R-spondin1 is a novel hormone mediator for mammary stem cell self-renewal |
| Q36200979 | RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDIN1. |
| Q38691526 | RANK as a therapeutic target in cancer. |
| Q52877576 | RANK expression as a prognostic and predictive marker in breast cancer. |
| Q39055979 | RANK expression on breast cancer cells promotes skeletal metastasis |
| Q40703245 | RANK ligand is a prerequisite for cancer-associated osteolytic lesions |
| Q28294501 | RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis |
| Q35641868 | RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini |
| Q47140509 | RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer. |
| Q36078073 | RANK, RANKL and osteoprotegerin in arthritic bone loss |
| Q37199218 | RANK, RANKL and osteoprotegerin in bone biology and disease. |
| Q35053943 | RANK-Fc: a therapeutic antagonist for RANK-L in myeloma |
| Q26747442 | RANK-RANKL signalling in cancer |
| Q48039377 | RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice |
| Q27674275 | RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor |
| Q29397534 | RANKL Is Necessary and Sufficient to Initiate Development of Antigen-Sampling M Cells in the Intestinal Epithelium |
| Q90547034 | RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women |
| Q89666841 | RANKL biology: bone metabolism, the immune system, and beyond |
| Q37865171 | RANKL inhibition: a promising novel strategy for breast cancer treatment. |
| Q44590687 | RANKL regulates endothelial cell survival through the phosphatidylinositol 3′‐kinase/Akt signal transduction pathway |
| Q47133428 | RANKL-mediated harmonious dialogue between fetus and mother guarantees smooth gestation by inducing decidual M2 macrophage polarization |
| Q89967663 | RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies |
| Q37457304 | RANKL/RANK control Brca1 mutation-driven mammary tumors |
| Q28308042 | RANKL/RANK-beyond bones |
| Q90152388 | RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling |
| Q60917149 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives |
| Q28075004 | RANKL/RANK: from bone loss to the prevention of breast cancer |
| Q42486557 | Rankl Impairs Lactogenic Differentiation Through Inhibition of the Prolactin/Stat5 Pathway at Midgestation. |
| Q49371326 | Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis |
| Q34870765 | Recent advances in inducible expression in transgenic mice |
| Q34750367 | Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit |
| Q34358320 | Receptor activator of NF-kappaB and podocytes: towards a function of a novel receptor-ligand pair in the survival response of podocyte injury |
| Q34302372 | Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2 |
| Q39347131 | Receptor activator of NF-κB ligand promotes proliferation of a putative mammary stem cell unique to the lactating epithelium. |
| Q34117448 | Receptor activator of nuclear factor kappa B ligand (RANKL): another link between breast and bone |
| Q73904964 | Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia |
| Q36860987 | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. |
| Q40298349 | Regulation of cancer cell migration and bone metastasis by RANKL. |
| Q34124144 | RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland |
| Q24802643 | Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development |
| Q64228473 | Reverse Signaling of Tumor Necrosis Factor Superfamily Proteins in Macrophages and Microglia: Superfamily Portrait in the Neuroimmune Interface |
| Q90450548 | Risk of Osteoporotic Fracture in Patients with Breast Cancer: Meta-Analysis |
| Q34963016 | Role of RANKL and RANK in bone loss and arthritis. |
| Q28283972 | Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system |
| Q37241255 | Role of RANKL/RANK in primary and secondary breast cancer |
| Q37978237 | Role of T cells in ovariectomy induced bone loss--revisited |
| Q36324952 | Role of interleukin-7 in bone and T-cell homeostasis |
| Q37143375 | Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice |
| Q34090842 | Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. |
| Q45929205 | Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents. |
| Q92602305 | Sex-determining region Y (SRY) attributes to gender differences in RANKL expression and incidence of osteoporosis |
| Q28513906 | Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium |
| Q33874455 | Signal transducer and activator of transcription 5a mediates mammary ductal branching and proliferation in the nulliparous mouse |
| Q34434909 | Signaling pathways in mammary gland development. |
| Q29616428 | Signalling pathways of the TNF superfamily: a double-edged sword |
| Q38471541 | Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species |
| Q38009712 | Skeletal and extraskeletal actions of denosumab. |
| Q61135621 | Soluble RANKL contributes to osteoclast formation in adult mice but not ovariectomy-induced bone loss |
| Q97643643 | Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone |
| Q43036665 | Stem cells: Cues from steroid hormones |
| Q34344554 | Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice |
| Q37125950 | Strain-specific differences in the mechanisms of progesterone regulation of murine mammary gland development |
| Q36045625 | Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. |
| Q24645558 | Stromal effects on mammary gland development and breast cancer |
| Q35598825 | Survival and differentiation of mammary epithelial cells in mammary gland development require nuclear retention of Id2 due to RANK signaling |
| Q27311542 | T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer |
| Q38042619 | TNF receptor family signaling in the development and functions of medullary thymic epithelial cells |
| Q34126306 | TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women |
| Q92513362 | TRAF6 maintains mammary stem cells and promotes pregnancy-induced mammary epithelial cell expansion |
| Q26849690 | Targeting RANKL in metastasis |
| Q34281611 | Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression. |
| Q44186063 | Targeting reverse tetracycline-dependent transactivator to murine mammary epithelial cells that express the progesterone receptor |
| Q98771227 | Targeting the RANKL/RANK/OPG Axis for Cancer Therapy |
| Q36356112 | The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis. |
| Q41200607 | The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. |
| Q28585870 | The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse |
| Q81414623 | The RANKL/RANK/OPG pathway |
| Q95643120 | The RNA binding protein CPEB2 regulates hormone sensing in mammary gland development and luminal breast cancer |
| Q28203717 | The TNF and TNF receptor superfamilies: integrating mammalian biology |
| Q35176348 | The TNF receptor superfamily: role in immune inflammation and bone formation |
| Q88954027 | The Tumor Necrosis Factor Superfamily Member RANKL Suppresses Effector Cytokine Production in Group 3 Innate Lymphoid Cells |
| Q35012730 | The alveolar switch: coordinating the proliferative cues and cell fate decisions that drive the formation of lobuloalveoli from ductal epithelium |
| Q33869676 | The association between the baseline bone resorption marker CTX and incident dysglycemia after 4 years |
| Q35868802 | The biology of progesterone receptor in the normal mammary gland and in breast cancer |
| Q35012999 | The mammary gland microenvironment directs progenitor cell fate in vivo |
| Q36905332 | The physiological costs of reproduction in small mammals |
| Q54487255 | The role of TNF-α and TNF superfamily members in the pathogenesis of calcific aortic valvular disease. |
| Q34645503 | The role of growth factors in tooth development |
| Q36640852 | The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals |
| Q55117611 | Therapeutic and Preventive Effects of Osteoclastogenesis Inhibitory Factor on Osteolysis, Proliferation of Mammary Tumor Cell and Induction of Cancer Stem Cells in the Bone Microenvironment. |
| Q39996337 | Transcriptional regulation of human RANK ligand gene expression by E2F1. |
| Q35001309 | Transcriptional regulation of the human TNFSF11 gene in T cells via a cell type-selective set of distal enhancers |
| Q37034915 | Transcriptional response of the murine mammary gland to acute progesterone exposure |
| Q35194008 | Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling |
| Q33733718 | Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. |
| Q36521118 | Unique Distal Enhancers Linked to the Mouse Tnfsf11 Gene Direct Tissue-Specific and Inflammation-Induced Expression of RANKL. |
| Q28250891 | Upregulation of ADAM19 in chronic allograft nephropathy |
| Q81673001 | Upregulation of receptor activator of nuclear factor-kappaB ligand expression in the thymic subcapsular, paraseptal, perivascular, and medullary epithelial cells during thymus regeneration |
| Q34590536 | Use of genetically engineered mice in drug discovery and development: wielding Occam's razor to prune the product portfolio |
| Q50540673 | Uterine Progesterone Receptor Expression, Conceptus Development, and Ovarian Function in Pigs Treated with RU 486 During Early Pregnancy1 |
| Q44534331 | Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand |
| Q28078337 | What Is Breast in the Bone? |
| Q26849473 | Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment? |
| Q91707946 | miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis |
| Q80439527 | sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis |
| Q34429126 | t10,c12-CLA decreases adiposity in peripubertal mice without dose-related detrimental effects on mammary development, inflammation status, and metabolism |
Search more.